Summary of studies describing the distribution pattern of lymph node metastases for esophageal squamous cell carcinoma
| Author SCC . | Year . | Country . | Study type . | Sample size . | Histology . | Location of primary tumor . | cT (y) and pT . | cN and (y)pN . | Oncological treatment . | Extent of lymphadenectomy . | Total number of LN . | Number of positive lymph nodes . | Distribution of LNM/lymph node stations most frequently involved . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| H. Li19 | 2012 | China | Retrospective | 200 | SCC | UTE 31 (16) MTE 137 (69) LTE 32 (16) | pT1 18 pT2 45 pT3 114 pT4 23 | NR | Adjuvant chemotherapy | 3FL | Mean 35.5 | NR | UTE Cervical 54.8% Recurrent laryngeal nerve 41.9% Mediastinal 51.6% Abdominal 0% MTE Cervical 35% Recurrent laryngeal nerve 34.3% Mediastinal 46% Abdominal 24.8% LTE Cervical 35% Recurrent laryngeal nerve 37.5% Mediastinal 56.3% Abdominal 37.5% |
| S. Sharma20 | 1994 | Japan | Retrospective | 70 | SCC | UTE 10 (14) MTE 37 (53) LTE 23 (33) | pT1 11 (16) pT2 12 (17) pT3 46 (65) pT5 1 (2) | pN0 20 (29) pN1 50 (71) | No preoperative therapy | 3FL | Mean 82 | 208/5720 (3.6%) | Cervical 17.1% Thoracic 51.4% Abdominal 42.9% |
| J. Chen20 | 2009 | China | Retrospective | 1850 | SCC | UTE 289 MTE 1381 LTE 180 | pT1 109 pT2 348 pT3 1215 pT4 178 | NR | No preoperative therapy | 3FL | Mean 26 (range 15–71) | 4350/47470 (9.2%) | UTE Cervical 49.5% Upper mediastinal 28.7% Middle mediastinal 11.4% Lower mediastinal 1.4% Abdominal 8.0% MTE Cervical 35.0% Upper mediastinal 22.4% Middle mediastinal 29.8% Lower mediastinal 6.0% Abdominal 27.2% LTE Cervical 17.2% Upper mediastinal 10.0% Middle mediastinal 25.6% Lower mediastinal 13.9% Abdominal 51.7% |
| S. Kosugi22 | 2013 | Japan | Retrospective | 86 | SCC | UTE 17 (20) MTE 59 (69) LTE 10 (11) | pT1 81 (95) pT2 (5) | NR | No preoperative therapy | 3FL | NR | NR | UTE Cervical 41% Upper mediastinal 24% Middle mediastinal 6% Lower Mediastinal 0% Abdominal 6% |
| MTE Cervical 13% Upper mediastinal 26% Middle mediastinal 5% Lower mediastinal 6% Abdominal 27% LTE Cervical 0% Upper mediastinal 0% Middle mediastinal 20% Lower mediastinal 10% Abdominal 40% | |||||||||||||
| Y. Tachimori23 | 2011 | Japan | Retrospective | 356 | SCC | UTE 55 (15) MTE 173 (49) LTE 128 (36) | pT1 127 (35.7) pT2 40 (11.2) pT3 183 (51.4) pT4 6 (1.7) | pN0 110 (30.9) pN1 116 (32.6) pN2 81 (22.8) pN3 49 (13.8) | No preoperative therapy | 3Fl | NR | NR | UTE Cervical 13.6% Upper mediastinal 54.5% Middle mediastinal 4.5% MTE Cervical 11.9% Upper mediastinal 22.4% Middle mediastinal 6.0% Lower mediastinal 9.0% Abdominal 26.9% LTE Upper mediastinal 13.2% Middle mediastinal 5.3% Lower mediastinal 5.3% Abdominal 39.5% |
| J. Cheng62 | 2013 | China | Retrospective | 1893 | SCC | UTE 82 (4.3) MTE 1266 (66.9) LTE 545 (28.7) | pTis 10 (0.5) pT1 103 (5.4) pT2 345 (18.2) pT3 1173 (62) pT4 262 (13.8) | NR | No preoperative therapy | 2FL or 3FL | Mean 13.4 | 856/1893 (45.7%) | UTE Cervical 14.6% Upper mediastinal 29.3% Middle mediastinal 8.5% Lower mediastinal 9.8% Abdominal 7.3% MTE Cervical 4.3% Upper mediastinal 5.0% Middle mediastinal 32.9% Lower mediastinal 2.5% Abdominal 14.9% LTE Cervical 2.0% Upper mediastinal 2.2% Middle mediastinal 15.4% Lower mediastinal 38.1% Abdominal 27.5% |
| Z. Lin63 | 2016 | China | Prospective | 260 | SCC | CE/UTE 28 (10.8) MTE 173 (66.5) LTE 59 (22.7) | pT1 30 (11.5) pT2 44 (16.9) pT3 164 (63.1) pT4 22 (8.5) | pN0 119 (45.8) pN1 67 (25.1) pN2 54 (20.8) pN3 20 (7.7) | No preoperative therapy | 2FL 107 (41.2) 3FL 153 (58.8) | Median 35 (IQR 25–46) | Median 1 (IQR 0–3) | CE/UTE (JES) Station 1 38.9% Station 2 29.3% Station 9 25.0% MTE (JES) Station 8 M 17.5% Station 1 22.9% Station 16 22.8% LTE (JES) Station 16 33.9% Station 8 L 26.7% Station 8 M 17.5% |
| S. Y. Park64 | 2018 | Republic of Korea | Prospective | 29 | SCC | MTE 17 (58.6) LTE 12 (41.4) | pT1 29 (100) | cN0 25 (86.2) cN1 4 (13.8) | No preoperative therapy | Total mediastinal | Mean 54.7 | NR | NR |
| H. Igaki65 | 2001 | Japan | Retrospective | 96 | SCC | LTE 96 (100) | pT1 27 (28) pT2 16 (17) pT3 53 (55) | pN0 36 (38) pN1 60 (63) | No preoperative therapy | 3FL | NR | NR | Cervical 8.3% Upper mediastinal 17.7% Middle mediastinal 18.8% Lower mediastinal 49.0% Abdominal 51.0% |
| Y. Dong66 | 2015 | China | Retrospective | 3587 | SCC | UTE 189 (5.3) MTE 1837 (51.2) LTE (43.5) | pT1 435 (14) pT2 935 (25) pT3 1993 (55) pT4 225 (6) | pN0 2223 (62) pN1 1233 (34) pN2 98 (3) pN3 33 (1) | No preoperative therapy | 2FL 3115 (86.8) 3FL 472 (13.2) | Mean 20 (range 16–50) | 2870/71 740 (4%) | UTE Cervical 11.1% Upper mediastinal 15.6% Middle mediastinal 2.2% Lower mediastinal 2.2% Abdominal 1.1% MTE Cervical 5.9% Upper mediastinal 5.2% Middle mediastinal 16.6% Lower mediastinal 4.1% Abdominal 15.3% LTE Cervical 1.8% Upper mediastinal 1.4% Middle mediastinal 14.4% Lower mediastinal 20.3% Abdominal 31.4% |
| H. Miyata69 | 2019 | Japan | Prospective | 561 | SCC | MTE 294 (52.4) LTE 267 (47.6) | pT0 37 (6.6) pT1 112 (20) pT2 87 (15.5) pT3 306 (54.5) pT4 19 (3.4) | pN0 170 (30.3) pN1 181 (32.4) pN2 106 (18.9) pN3 104 (18.5) | NCRT (2 courses of ACF or DCF) | 2FL 242 (43.1) 3FL 319 (56.8) | Mean 70.4 | Number of positive nodes 4.4 (± 10) | NR |
| B. Li72 | 2020 | China | RCT | 400 | SCC | MTE 281 (70.3) LTE 119 (29.8) | pT1 102 (25.5) pT2 96 (24) pT3 178 (44.5) pT4 24 (6) | pN0 205 (51.3) pN1 104 (26) pN2 60 (15) pN3 31 (7.8) | No preoperative therapy | 3FL 2FL | 3FL: median 37 (IQR 30–49) 2FL: median 24 (18–30) | NR | 3FL Cervical 21.5% Thoracic 34.5% Abdominal 31.0% 2FL Thoracic 36.5% Abdominal 28.5% |
| Author SCC . | Year . | Country . | Study type . | Sample size . | Histology . | Location of primary tumor . | cT (y) and pT . | cN and (y)pN . | Oncological treatment . | Extent of lymphadenectomy . | Total number of LN . | Number of positive lymph nodes . | Distribution of LNM/lymph node stations most frequently involved . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| H. Li19 | 2012 | China | Retrospective | 200 | SCC | UTE 31 (16) MTE 137 (69) LTE 32 (16) | pT1 18 pT2 45 pT3 114 pT4 23 | NR | Adjuvant chemotherapy | 3FL | Mean 35.5 | NR | UTE Cervical 54.8% Recurrent laryngeal nerve 41.9% Mediastinal 51.6% Abdominal 0% MTE Cervical 35% Recurrent laryngeal nerve 34.3% Mediastinal 46% Abdominal 24.8% LTE Cervical 35% Recurrent laryngeal nerve 37.5% Mediastinal 56.3% Abdominal 37.5% |
| S. Sharma20 | 1994 | Japan | Retrospective | 70 | SCC | UTE 10 (14) MTE 37 (53) LTE 23 (33) | pT1 11 (16) pT2 12 (17) pT3 46 (65) pT5 1 (2) | pN0 20 (29) pN1 50 (71) | No preoperative therapy | 3FL | Mean 82 | 208/5720 (3.6%) | Cervical 17.1% Thoracic 51.4% Abdominal 42.9% |
| J. Chen20 | 2009 | China | Retrospective | 1850 | SCC | UTE 289 MTE 1381 LTE 180 | pT1 109 pT2 348 pT3 1215 pT4 178 | NR | No preoperative therapy | 3FL | Mean 26 (range 15–71) | 4350/47470 (9.2%) | UTE Cervical 49.5% Upper mediastinal 28.7% Middle mediastinal 11.4% Lower mediastinal 1.4% Abdominal 8.0% MTE Cervical 35.0% Upper mediastinal 22.4% Middle mediastinal 29.8% Lower mediastinal 6.0% Abdominal 27.2% LTE Cervical 17.2% Upper mediastinal 10.0% Middle mediastinal 25.6% Lower mediastinal 13.9% Abdominal 51.7% |
| S. Kosugi22 | 2013 | Japan | Retrospective | 86 | SCC | UTE 17 (20) MTE 59 (69) LTE 10 (11) | pT1 81 (95) pT2 (5) | NR | No preoperative therapy | 3FL | NR | NR | UTE Cervical 41% Upper mediastinal 24% Middle mediastinal 6% Lower Mediastinal 0% Abdominal 6% |
| MTE Cervical 13% Upper mediastinal 26% Middle mediastinal 5% Lower mediastinal 6% Abdominal 27% LTE Cervical 0% Upper mediastinal 0% Middle mediastinal 20% Lower mediastinal 10% Abdominal 40% | |||||||||||||
| Y. Tachimori23 | 2011 | Japan | Retrospective | 356 | SCC | UTE 55 (15) MTE 173 (49) LTE 128 (36) | pT1 127 (35.7) pT2 40 (11.2) pT3 183 (51.4) pT4 6 (1.7) | pN0 110 (30.9) pN1 116 (32.6) pN2 81 (22.8) pN3 49 (13.8) | No preoperative therapy | 3Fl | NR | NR | UTE Cervical 13.6% Upper mediastinal 54.5% Middle mediastinal 4.5% MTE Cervical 11.9% Upper mediastinal 22.4% Middle mediastinal 6.0% Lower mediastinal 9.0% Abdominal 26.9% LTE Upper mediastinal 13.2% Middle mediastinal 5.3% Lower mediastinal 5.3% Abdominal 39.5% |
| J. Cheng62 | 2013 | China | Retrospective | 1893 | SCC | UTE 82 (4.3) MTE 1266 (66.9) LTE 545 (28.7) | pTis 10 (0.5) pT1 103 (5.4) pT2 345 (18.2) pT3 1173 (62) pT4 262 (13.8) | NR | No preoperative therapy | 2FL or 3FL | Mean 13.4 | 856/1893 (45.7%) | UTE Cervical 14.6% Upper mediastinal 29.3% Middle mediastinal 8.5% Lower mediastinal 9.8% Abdominal 7.3% MTE Cervical 4.3% Upper mediastinal 5.0% Middle mediastinal 32.9% Lower mediastinal 2.5% Abdominal 14.9% LTE Cervical 2.0% Upper mediastinal 2.2% Middle mediastinal 15.4% Lower mediastinal 38.1% Abdominal 27.5% |
| Z. Lin63 | 2016 | China | Prospective | 260 | SCC | CE/UTE 28 (10.8) MTE 173 (66.5) LTE 59 (22.7) | pT1 30 (11.5) pT2 44 (16.9) pT3 164 (63.1) pT4 22 (8.5) | pN0 119 (45.8) pN1 67 (25.1) pN2 54 (20.8) pN3 20 (7.7) | No preoperative therapy | 2FL 107 (41.2) 3FL 153 (58.8) | Median 35 (IQR 25–46) | Median 1 (IQR 0–3) | CE/UTE (JES) Station 1 38.9% Station 2 29.3% Station 9 25.0% MTE (JES) Station 8 M 17.5% Station 1 22.9% Station 16 22.8% LTE (JES) Station 16 33.9% Station 8 L 26.7% Station 8 M 17.5% |
| S. Y. Park64 | 2018 | Republic of Korea | Prospective | 29 | SCC | MTE 17 (58.6) LTE 12 (41.4) | pT1 29 (100) | cN0 25 (86.2) cN1 4 (13.8) | No preoperative therapy | Total mediastinal | Mean 54.7 | NR | NR |
| H. Igaki65 | 2001 | Japan | Retrospective | 96 | SCC | LTE 96 (100) | pT1 27 (28) pT2 16 (17) pT3 53 (55) | pN0 36 (38) pN1 60 (63) | No preoperative therapy | 3FL | NR | NR | Cervical 8.3% Upper mediastinal 17.7% Middle mediastinal 18.8% Lower mediastinal 49.0% Abdominal 51.0% |
| Y. Dong66 | 2015 | China | Retrospective | 3587 | SCC | UTE 189 (5.3) MTE 1837 (51.2) LTE (43.5) | pT1 435 (14) pT2 935 (25) pT3 1993 (55) pT4 225 (6) | pN0 2223 (62) pN1 1233 (34) pN2 98 (3) pN3 33 (1) | No preoperative therapy | 2FL 3115 (86.8) 3FL 472 (13.2) | Mean 20 (range 16–50) | 2870/71 740 (4%) | UTE Cervical 11.1% Upper mediastinal 15.6% Middle mediastinal 2.2% Lower mediastinal 2.2% Abdominal 1.1% MTE Cervical 5.9% Upper mediastinal 5.2% Middle mediastinal 16.6% Lower mediastinal 4.1% Abdominal 15.3% LTE Cervical 1.8% Upper mediastinal 1.4% Middle mediastinal 14.4% Lower mediastinal 20.3% Abdominal 31.4% |
| H. Miyata69 | 2019 | Japan | Prospective | 561 | SCC | MTE 294 (52.4) LTE 267 (47.6) | pT0 37 (6.6) pT1 112 (20) pT2 87 (15.5) pT3 306 (54.5) pT4 19 (3.4) | pN0 170 (30.3) pN1 181 (32.4) pN2 106 (18.9) pN3 104 (18.5) | NCRT (2 courses of ACF or DCF) | 2FL 242 (43.1) 3FL 319 (56.8) | Mean 70.4 | Number of positive nodes 4.4 (± 10) | NR |
| B. Li72 | 2020 | China | RCT | 400 | SCC | MTE 281 (70.3) LTE 119 (29.8) | pT1 102 (25.5) pT2 96 (24) pT3 178 (44.5) pT4 24 (6) | pN0 205 (51.3) pN1 104 (26) pN2 60 (15) pN3 31 (7.8) | No preoperative therapy | 3FL 2FL | 3FL: median 37 (IQR 30–49) 2FL: median 24 (18–30) | NR | 3FL Cervical 21.5% Thoracic 34.5% Abdominal 31.0% 2FL Thoracic 36.5% Abdominal 28.5% |
Summary of studies describing the distribution pattern of lymph node metastases for esophageal squamous cell carcinoma
| Author SCC . | Year . | Country . | Study type . | Sample size . | Histology . | Location of primary tumor . | cT (y) and pT . | cN and (y)pN . | Oncological treatment . | Extent of lymphadenectomy . | Total number of LN . | Number of positive lymph nodes . | Distribution of LNM/lymph node stations most frequently involved . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| H. Li19 | 2012 | China | Retrospective | 200 | SCC | UTE 31 (16) MTE 137 (69) LTE 32 (16) | pT1 18 pT2 45 pT3 114 pT4 23 | NR | Adjuvant chemotherapy | 3FL | Mean 35.5 | NR | UTE Cervical 54.8% Recurrent laryngeal nerve 41.9% Mediastinal 51.6% Abdominal 0% MTE Cervical 35% Recurrent laryngeal nerve 34.3% Mediastinal 46% Abdominal 24.8% LTE Cervical 35% Recurrent laryngeal nerve 37.5% Mediastinal 56.3% Abdominal 37.5% |
| S. Sharma20 | 1994 | Japan | Retrospective | 70 | SCC | UTE 10 (14) MTE 37 (53) LTE 23 (33) | pT1 11 (16) pT2 12 (17) pT3 46 (65) pT5 1 (2) | pN0 20 (29) pN1 50 (71) | No preoperative therapy | 3FL | Mean 82 | 208/5720 (3.6%) | Cervical 17.1% Thoracic 51.4% Abdominal 42.9% |
| J. Chen20 | 2009 | China | Retrospective | 1850 | SCC | UTE 289 MTE 1381 LTE 180 | pT1 109 pT2 348 pT3 1215 pT4 178 | NR | No preoperative therapy | 3FL | Mean 26 (range 15–71) | 4350/47470 (9.2%) | UTE Cervical 49.5% Upper mediastinal 28.7% Middle mediastinal 11.4% Lower mediastinal 1.4% Abdominal 8.0% MTE Cervical 35.0% Upper mediastinal 22.4% Middle mediastinal 29.8% Lower mediastinal 6.0% Abdominal 27.2% LTE Cervical 17.2% Upper mediastinal 10.0% Middle mediastinal 25.6% Lower mediastinal 13.9% Abdominal 51.7% |
| S. Kosugi22 | 2013 | Japan | Retrospective | 86 | SCC | UTE 17 (20) MTE 59 (69) LTE 10 (11) | pT1 81 (95) pT2 (5) | NR | No preoperative therapy | 3FL | NR | NR | UTE Cervical 41% Upper mediastinal 24% Middle mediastinal 6% Lower Mediastinal 0% Abdominal 6% |
| MTE Cervical 13% Upper mediastinal 26% Middle mediastinal 5% Lower mediastinal 6% Abdominal 27% LTE Cervical 0% Upper mediastinal 0% Middle mediastinal 20% Lower mediastinal 10% Abdominal 40% | |||||||||||||
| Y. Tachimori23 | 2011 | Japan | Retrospective | 356 | SCC | UTE 55 (15) MTE 173 (49) LTE 128 (36) | pT1 127 (35.7) pT2 40 (11.2) pT3 183 (51.4) pT4 6 (1.7) | pN0 110 (30.9) pN1 116 (32.6) pN2 81 (22.8) pN3 49 (13.8) | No preoperative therapy | 3Fl | NR | NR | UTE Cervical 13.6% Upper mediastinal 54.5% Middle mediastinal 4.5% MTE Cervical 11.9% Upper mediastinal 22.4% Middle mediastinal 6.0% Lower mediastinal 9.0% Abdominal 26.9% LTE Upper mediastinal 13.2% Middle mediastinal 5.3% Lower mediastinal 5.3% Abdominal 39.5% |
| J. Cheng62 | 2013 | China | Retrospective | 1893 | SCC | UTE 82 (4.3) MTE 1266 (66.9) LTE 545 (28.7) | pTis 10 (0.5) pT1 103 (5.4) pT2 345 (18.2) pT3 1173 (62) pT4 262 (13.8) | NR | No preoperative therapy | 2FL or 3FL | Mean 13.4 | 856/1893 (45.7%) | UTE Cervical 14.6% Upper mediastinal 29.3% Middle mediastinal 8.5% Lower mediastinal 9.8% Abdominal 7.3% MTE Cervical 4.3% Upper mediastinal 5.0% Middle mediastinal 32.9% Lower mediastinal 2.5% Abdominal 14.9% LTE Cervical 2.0% Upper mediastinal 2.2% Middle mediastinal 15.4% Lower mediastinal 38.1% Abdominal 27.5% |
| Z. Lin63 | 2016 | China | Prospective | 260 | SCC | CE/UTE 28 (10.8) MTE 173 (66.5) LTE 59 (22.7) | pT1 30 (11.5) pT2 44 (16.9) pT3 164 (63.1) pT4 22 (8.5) | pN0 119 (45.8) pN1 67 (25.1) pN2 54 (20.8) pN3 20 (7.7) | No preoperative therapy | 2FL 107 (41.2) 3FL 153 (58.8) | Median 35 (IQR 25–46) | Median 1 (IQR 0–3) | CE/UTE (JES) Station 1 38.9% Station 2 29.3% Station 9 25.0% MTE (JES) Station 8 M 17.5% Station 1 22.9% Station 16 22.8% LTE (JES) Station 16 33.9% Station 8 L 26.7% Station 8 M 17.5% |
| S. Y. Park64 | 2018 | Republic of Korea | Prospective | 29 | SCC | MTE 17 (58.6) LTE 12 (41.4) | pT1 29 (100) | cN0 25 (86.2) cN1 4 (13.8) | No preoperative therapy | Total mediastinal | Mean 54.7 | NR | NR |
| H. Igaki65 | 2001 | Japan | Retrospective | 96 | SCC | LTE 96 (100) | pT1 27 (28) pT2 16 (17) pT3 53 (55) | pN0 36 (38) pN1 60 (63) | No preoperative therapy | 3FL | NR | NR | Cervical 8.3% Upper mediastinal 17.7% Middle mediastinal 18.8% Lower mediastinal 49.0% Abdominal 51.0% |
| Y. Dong66 | 2015 | China | Retrospective | 3587 | SCC | UTE 189 (5.3) MTE 1837 (51.2) LTE (43.5) | pT1 435 (14) pT2 935 (25) pT3 1993 (55) pT4 225 (6) | pN0 2223 (62) pN1 1233 (34) pN2 98 (3) pN3 33 (1) | No preoperative therapy | 2FL 3115 (86.8) 3FL 472 (13.2) | Mean 20 (range 16–50) | 2870/71 740 (4%) | UTE Cervical 11.1% Upper mediastinal 15.6% Middle mediastinal 2.2% Lower mediastinal 2.2% Abdominal 1.1% MTE Cervical 5.9% Upper mediastinal 5.2% Middle mediastinal 16.6% Lower mediastinal 4.1% Abdominal 15.3% LTE Cervical 1.8% Upper mediastinal 1.4% Middle mediastinal 14.4% Lower mediastinal 20.3% Abdominal 31.4% |
| H. Miyata69 | 2019 | Japan | Prospective | 561 | SCC | MTE 294 (52.4) LTE 267 (47.6) | pT0 37 (6.6) pT1 112 (20) pT2 87 (15.5) pT3 306 (54.5) pT4 19 (3.4) | pN0 170 (30.3) pN1 181 (32.4) pN2 106 (18.9) pN3 104 (18.5) | NCRT (2 courses of ACF or DCF) | 2FL 242 (43.1) 3FL 319 (56.8) | Mean 70.4 | Number of positive nodes 4.4 (± 10) | NR |
| B. Li72 | 2020 | China | RCT | 400 | SCC | MTE 281 (70.3) LTE 119 (29.8) | pT1 102 (25.5) pT2 96 (24) pT3 178 (44.5) pT4 24 (6) | pN0 205 (51.3) pN1 104 (26) pN2 60 (15) pN3 31 (7.8) | No preoperative therapy | 3FL 2FL | 3FL: median 37 (IQR 30–49) 2FL: median 24 (18–30) | NR | 3FL Cervical 21.5% Thoracic 34.5% Abdominal 31.0% 2FL Thoracic 36.5% Abdominal 28.5% |
| Author SCC . | Year . | Country . | Study type . | Sample size . | Histology . | Location of primary tumor . | cT (y) and pT . | cN and (y)pN . | Oncological treatment . | Extent of lymphadenectomy . | Total number of LN . | Number of positive lymph nodes . | Distribution of LNM/lymph node stations most frequently involved . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| H. Li19 | 2012 | China | Retrospective | 200 | SCC | UTE 31 (16) MTE 137 (69) LTE 32 (16) | pT1 18 pT2 45 pT3 114 pT4 23 | NR | Adjuvant chemotherapy | 3FL | Mean 35.5 | NR | UTE Cervical 54.8% Recurrent laryngeal nerve 41.9% Mediastinal 51.6% Abdominal 0% MTE Cervical 35% Recurrent laryngeal nerve 34.3% Mediastinal 46% Abdominal 24.8% LTE Cervical 35% Recurrent laryngeal nerve 37.5% Mediastinal 56.3% Abdominal 37.5% |
| S. Sharma20 | 1994 | Japan | Retrospective | 70 | SCC | UTE 10 (14) MTE 37 (53) LTE 23 (33) | pT1 11 (16) pT2 12 (17) pT3 46 (65) pT5 1 (2) | pN0 20 (29) pN1 50 (71) | No preoperative therapy | 3FL | Mean 82 | 208/5720 (3.6%) | Cervical 17.1% Thoracic 51.4% Abdominal 42.9% |
| J. Chen20 | 2009 | China | Retrospective | 1850 | SCC | UTE 289 MTE 1381 LTE 180 | pT1 109 pT2 348 pT3 1215 pT4 178 | NR | No preoperative therapy | 3FL | Mean 26 (range 15–71) | 4350/47470 (9.2%) | UTE Cervical 49.5% Upper mediastinal 28.7% Middle mediastinal 11.4% Lower mediastinal 1.4% Abdominal 8.0% MTE Cervical 35.0% Upper mediastinal 22.4% Middle mediastinal 29.8% Lower mediastinal 6.0% Abdominal 27.2% LTE Cervical 17.2% Upper mediastinal 10.0% Middle mediastinal 25.6% Lower mediastinal 13.9% Abdominal 51.7% |
| S. Kosugi22 | 2013 | Japan | Retrospective | 86 | SCC | UTE 17 (20) MTE 59 (69) LTE 10 (11) | pT1 81 (95) pT2 (5) | NR | No preoperative therapy | 3FL | NR | NR | UTE Cervical 41% Upper mediastinal 24% Middle mediastinal 6% Lower Mediastinal 0% Abdominal 6% |
| MTE Cervical 13% Upper mediastinal 26% Middle mediastinal 5% Lower mediastinal 6% Abdominal 27% LTE Cervical 0% Upper mediastinal 0% Middle mediastinal 20% Lower mediastinal 10% Abdominal 40% | |||||||||||||
| Y. Tachimori23 | 2011 | Japan | Retrospective | 356 | SCC | UTE 55 (15) MTE 173 (49) LTE 128 (36) | pT1 127 (35.7) pT2 40 (11.2) pT3 183 (51.4) pT4 6 (1.7) | pN0 110 (30.9) pN1 116 (32.6) pN2 81 (22.8) pN3 49 (13.8) | No preoperative therapy | 3Fl | NR | NR | UTE Cervical 13.6% Upper mediastinal 54.5% Middle mediastinal 4.5% MTE Cervical 11.9% Upper mediastinal 22.4% Middle mediastinal 6.0% Lower mediastinal 9.0% Abdominal 26.9% LTE Upper mediastinal 13.2% Middle mediastinal 5.3% Lower mediastinal 5.3% Abdominal 39.5% |
| J. Cheng62 | 2013 | China | Retrospective | 1893 | SCC | UTE 82 (4.3) MTE 1266 (66.9) LTE 545 (28.7) | pTis 10 (0.5) pT1 103 (5.4) pT2 345 (18.2) pT3 1173 (62) pT4 262 (13.8) | NR | No preoperative therapy | 2FL or 3FL | Mean 13.4 | 856/1893 (45.7%) | UTE Cervical 14.6% Upper mediastinal 29.3% Middle mediastinal 8.5% Lower mediastinal 9.8% Abdominal 7.3% MTE Cervical 4.3% Upper mediastinal 5.0% Middle mediastinal 32.9% Lower mediastinal 2.5% Abdominal 14.9% LTE Cervical 2.0% Upper mediastinal 2.2% Middle mediastinal 15.4% Lower mediastinal 38.1% Abdominal 27.5% |
| Z. Lin63 | 2016 | China | Prospective | 260 | SCC | CE/UTE 28 (10.8) MTE 173 (66.5) LTE 59 (22.7) | pT1 30 (11.5) pT2 44 (16.9) pT3 164 (63.1) pT4 22 (8.5) | pN0 119 (45.8) pN1 67 (25.1) pN2 54 (20.8) pN3 20 (7.7) | No preoperative therapy | 2FL 107 (41.2) 3FL 153 (58.8) | Median 35 (IQR 25–46) | Median 1 (IQR 0–3) | CE/UTE (JES) Station 1 38.9% Station 2 29.3% Station 9 25.0% MTE (JES) Station 8 M 17.5% Station 1 22.9% Station 16 22.8% LTE (JES) Station 16 33.9% Station 8 L 26.7% Station 8 M 17.5% |
| S. Y. Park64 | 2018 | Republic of Korea | Prospective | 29 | SCC | MTE 17 (58.6) LTE 12 (41.4) | pT1 29 (100) | cN0 25 (86.2) cN1 4 (13.8) | No preoperative therapy | Total mediastinal | Mean 54.7 | NR | NR |
| H. Igaki65 | 2001 | Japan | Retrospective | 96 | SCC | LTE 96 (100) | pT1 27 (28) pT2 16 (17) pT3 53 (55) | pN0 36 (38) pN1 60 (63) | No preoperative therapy | 3FL | NR | NR | Cervical 8.3% Upper mediastinal 17.7% Middle mediastinal 18.8% Lower mediastinal 49.0% Abdominal 51.0% |
| Y. Dong66 | 2015 | China | Retrospective | 3587 | SCC | UTE 189 (5.3) MTE 1837 (51.2) LTE (43.5) | pT1 435 (14) pT2 935 (25) pT3 1993 (55) pT4 225 (6) | pN0 2223 (62) pN1 1233 (34) pN2 98 (3) pN3 33 (1) | No preoperative therapy | 2FL 3115 (86.8) 3FL 472 (13.2) | Mean 20 (range 16–50) | 2870/71 740 (4%) | UTE Cervical 11.1% Upper mediastinal 15.6% Middle mediastinal 2.2% Lower mediastinal 2.2% Abdominal 1.1% MTE Cervical 5.9% Upper mediastinal 5.2% Middle mediastinal 16.6% Lower mediastinal 4.1% Abdominal 15.3% LTE Cervical 1.8% Upper mediastinal 1.4% Middle mediastinal 14.4% Lower mediastinal 20.3% Abdominal 31.4% |
| H. Miyata69 | 2019 | Japan | Prospective | 561 | SCC | MTE 294 (52.4) LTE 267 (47.6) | pT0 37 (6.6) pT1 112 (20) pT2 87 (15.5) pT3 306 (54.5) pT4 19 (3.4) | pN0 170 (30.3) pN1 181 (32.4) pN2 106 (18.9) pN3 104 (18.5) | NCRT (2 courses of ACF or DCF) | 2FL 242 (43.1) 3FL 319 (56.8) | Mean 70.4 | Number of positive nodes 4.4 (± 10) | NR |
| B. Li72 | 2020 | China | RCT | 400 | SCC | MTE 281 (70.3) LTE 119 (29.8) | pT1 102 (25.5) pT2 96 (24) pT3 178 (44.5) pT4 24 (6) | pN0 205 (51.3) pN1 104 (26) pN2 60 (15) pN3 31 (7.8) | No preoperative therapy | 3FL 2FL | 3FL: median 37 (IQR 30–49) 2FL: median 24 (18–30) | NR | 3FL Cervical 21.5% Thoracic 34.5% Abdominal 31.0% 2FL Thoracic 36.5% Abdominal 28.5% |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
